Gemigliptin and Biomarkers of Kidney Injury and Vascular Calcification
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glycemic control and contain pleiotropic
actions on kidney injury, albuminuria and vascular inflammation especially in animal models.
We plan to evaluate the efficacy of potent DPP4-inhibitors (gemigliptin) in response to these
aspects in diabetic nephropathy patients.
Phase:
N/A
Details
Lead Sponsor:
Bangkok Metropolitan Administration Medical College and Vajira Hospital